NAC (N-acetyl cysteine)

N-Acetyl Cysteine (NAC): Comprehensive Reference Article

1. Identity and Chemical Characterization

Nomenclature

N-acetyl-L-cysteine is the acetylated precursor of the amino acid L-cysteine and is also known as N-acetyl cysteine, N-acetyl-L-cysteine, or NAC. Its molecular formula is C₅H₉NO₃S; it is an acetylated derivative of cysteine, a sulphur-containing amino acid. NAC carries the IUPAC name 2-acetamido-3-sulfanylpropanoic acid and its International Nonproprietary Name (INN) is acetylcysteine. The compound is sometimes rendered in older literature as mercaptoacetyl glycine or simply Mucomyst, the latter being a widely recognized brand name for its inhaled pharmaceutical formulation.

Structure and Key Chemical Properties

NAC is a derivative of cysteine with an acetyl group attached to its nitrogen atom and, like most thiols (RSH), can be oxidized by a large variety of radicals and also serve as a nucleophile (electron pair donor). NAC is a metal-binding compound, as is the case with other thiols, having two potential coordination sites at the thiol and carboxyl groups where the latter is deprotonated at neutral pH. NAC is capable of binding transition metal ions such as Zn(II), Mg(II), and Fe(III), and heavy metal ions such as Cd(II), Hg(II), and Pb(II), primarily through its thiol side chain. By chelating toxic metal ions, NAC forms complex structures that are readily excreted from the body, removing them from intracellular or extracellular spaces.

Natural Sources of Cysteine and the Dietary Context of NAC

NAC itself is not found in natural sources, although cysteine is present in some meals like chicken and turkey meats, garlic, yogurt, and eggs. Cysteine is found naturally in meat, fish, grains, dairy, soybean, and egg products. One peer-reviewed source notes that NAC is a plant antioxidant naturally found in onion, though the quantitatively dominant route of human exposure to NAC is through pharmaceutical or dietary supplement preparations rather than dietary intake of the molecule itself.

Commercial Synthesis and Preparations

NAC is synthesized through chemical modification of L-cysteine by adding an acetyl group. This acetylation process improves the stability and bioavailability of cysteine, making it more effective as a supplement ingredient. The L-cysteine used as the starting material can be produced through fermentation processes or extracted from protein-rich sources.

NAC is available in the following principal dosage forms:

• Oral solid forms: Capsules, tablets, and effervescent tablets — the most common forms used in dietary supplementation and oral pharmaceutical therapy.
• Oral solutions and effervescent granules: Used clinically for acetaminophen overdose and as a mucolytic.
• Inhalation solutions: For the mucolytic effect, the first NAC formulations were inhalations.
• Intravenous (IV) solutions: Not long after the inhaled form, NAC was proven to be equally effective in peroral (PO) or parenteral administration. Compared to oral administration, the mucolytic effect of IV NAC has a more rapid onset of action, but there is no significant difference in long-term effects.
• Novel derivative forms: N-acetylcysteine amide (AD4/NACA) is a cell-permeant amide form of NAC that has demonstrated superior chemical effectiveness than NAC in various studies. An ethyl ester form (NACET) has also been marketed, though human pharmacokinetic data for this form remain limited.

NAC has a fascinating dual identity — it is both an FDA-approved pharmaceutical drug and a popular dietary supplement ingredient.

2. Historical and Medical Development

Chronology of Pharmaceutical Use

The history of N-acetylcysteine (NAC) began with its clinical use as a mucolytic agent in the 1960s. NAC is a sulfhydryl-containing compound with mucolytic properties, originally patented in 1960, and its use in medicine was first reported in 1967. Clinically, it has been used in cystic fibrosis since 1969.

The increase in hepatotoxicity secondary to acetaminophen overdose in the 1960s and 1970s prompted a search for an antidote. A series of key discoveries in the pathophysiology of acetaminophen-induced hepatotoxicity from the National Institutes of Health (NIH) elucidated critical components required of an antidote: the presence of a sulfhydryl group and the ability to replete glutathione stores. Work out of the United Kingdom and the United States found NAC to be superior to other sulfhydryl-containing compounds in preventing hepatotoxicity secondary to acetaminophen poisoning.

NAC was first introduced in 1965 primarily for its role in promoting mucolysis and has been the preferred treatment for paracetamol intoxication since the mid-1970s. Its intravenous formulation for this purpose is recognized on the WHO's List of Essential Medicines.

It has been used as a drug since the 1960s and is listed on the World Health Organization (WHO) Model List of Essential Medicines as an antidote in poisonings. Despite its discovery in the early 1960s and its development for various indications, systematic clinical pharmacology explorations of NAC pharmacokinetics (PK), pharmacodynamic targets, drug interactions, and dose-ranging are sorely limited.

Traditional and Pre-Clinical History

NAC as a discrete chemical entity has no traditional herbal or ethnobotanical history in the classical sense. It is a synthetic modification of a naturally occurring amino acid rather than a botanically derived remedy. Its parent compound, L-cysteine, exists as a component of dietary proteins, but NAC itself entered human medicine through pharmaceutical development in the mid-twentieth century, not through any folk or traditional system. NAC's medicinal usage was first reported in 1967 in the prophylaxis of meconium ileus equivalent. The rapid expansion of its indications thereafter was driven by laboratory and clinical research rather than traditional usage.

3. Active Constituents and Mechanisms of Action

The Thiol Group: Central Biochemical Identity

The features of NAC are mainly related to its thiol group, which makes it effective in most biochemical pathways where glutathione (GSH) acts. NAC is processed by cells to L-cysteine and is used in the de novo synthesis of GSH, thus being considered a precursor of GSH. Although details of NAC mechanisms of action are not completely understood, they are undoubtedly attributed to its thiol group. It is involved in the complex redox cycling of thiol groups in the cell, thereby affecting the regulation of the redox state of the cell as well as intracellular and intercellular signaling.

Glutathione Precursor Activity

NAC is a membrane-permeable cysteine precursor that does not require active transport and delivers cysteine to the cell in a unique way. After free NAC enters a cell, it is rapidly hydrolyzed to release cysteine, a precursor of glutathione (GSH). GSH is synthesized intracellularly by the consecutive actions of γ-glutamylcysteine synthetase and GSH synthetase. The synthesis of GSH is limited by the availability of substrates; cysteine is usually the limiting precursor.

Among many established roles for GSH are: antioxidant defense; detoxification of electrophilic xenobiotics; modulation of redox-regulated signal transduction; storage and transport of cysteine; regulation of cell proliferation and synthesis of deoxyribonucleotides; regulation of immune responses; and regulation of leukotriene and prostaglandin metabolism.

A key conceptual clarification has emerged from reviews of NAC's antioxidant role: NAC should not be considered to be a powerful antioxidant in its own right; its strength is the targeted replenishment of GSH in deficient cells and it is likely to be ineffective in cells replete in GSH.

Direct Free Radical Scavenging

NAC is a thiol, a mucolytic agent, and a precursor of L-cysteine and reduced GSH. NAC is a source of sulfhydryl groups in cells and a scavenger of free radicals as it interacts with reactive oxygen species (ROS) such as OH• and H₂O₂. NAC acts on thiolated proteins by releasing free thiols which may act as antioxidant agents. Direct antioxidant properties of NAC have also been observed in vitro, but the in vivo effect is not significant due to competition with endogenous enzymes.

Anti-Inflammatory Mechanisms

The primary role of NAC as an antioxidant stems from its ability to increase the intracellular concentration of GSH. As an anti-inflammatory compound, NAC can reduce levels of tumor necrosis factor-alpha (TNF-α) and interleukins (IL-6 and IL-1β) by suppressing the activity of nuclear factor kappa B (NF-κB).

NAC's anti-inflammatory activity is noteworthy, and it is not solely secondary to its antioxidant capabilities. In ex vivo models of COPD exacerbation, the anti-inflammatory effects have been observed even at very low doses, especially with prolonged treatment. The mechanism involves the inhibition of NF-κB and neurokinin A production, resulting in a reduction in interleukin-6 production, a cytokine abundantly present in the sputum and breath condensate of patients with COPD that correlates with the number of exacerbations.

Nrf2/ARE Pathway Modulation

NAC modulates the Nrf2/ARE signaling pathway, enhancing the transcription of antioxidant genes. This pathway is a master regulatory system of the cellular antioxidant response, and its activation by NAC (via GSH replenishment and thiol redox signaling) represents an important indirect mechanism beyond simple scavenging.

Glutamatergic Modulation

Over the past decade, there has been growing evidence for the use of NAC in treating psychiatric and neurological disorders, considering its role in attenuating pathophysiological processes associated with these disorders, including oxidative stress, apoptosis, mitochondrial dysfunction, neuroinflammation and glutamate and dopamine dysregulation. NAC, as a precursor to the antioxidant glutathione, modulates glutamatergic, neurotrophic, and inflammatory pathways.

Metal Chelation

NAC is capable of binding transition metal ions such as Zn(II), Mg(II), and Fe(III), and heavy metal ions such as Cd(II), Hg(II), and Pb(II) primarily through its thiol side chain. By chelating toxic metal ions, NAC forms complex structures that are readily excreted from the body, removing them from intracellular or extracellular spaces.

Mucolytic Action

NAC is a well-tolerated mucolytic drug that moderates clinging mucous secretions and enhances glutathione S-transferase activity. The mucolytic mechanism operates through the thiol group cleaving disulfide bonds within mucus glycoproteins, thereby reducing mucus viscosity and facilitating expectoration.

4. Pharmacokinetics and Bioavailability

Oral Bioavailability

The bioavailability of free NAC is very low (<10%), and only a tiny amount of the intact molecule reaches the plasma and tissues. Additionally, due to the variety of ways that NAC can be found in plasma (oxidized, reduced, and bound to proteins), its pharmacokinetics are not yet fully understood.

The bioavailability of oral NAC in humans is between 4 and 9.1% in one study and between 6 and 10% in another; thus, studies using less than 1200 mg per day may show no significant benefit. In critically ill patients, oral bioavailability was estimated as 11.6% (95% CI 6.3–16.9%), similar to bioavailability in healthy volunteers and patients with chronic pulmonary diseases.

Absolute bioavailability of oral NAC has been proven to be low, varying between 6–10%, probably due to extensive first-pass metabolism in the gut. During oral administration, deacetylation of NAC happens while passing along the small intestine as well as the liver, thus its bioavailability is decreased to 4–10%.

Metabolism

Biotransformation of NAC leads to the formation of metabolites including disulfide, cysteine, and conjugates (N,N-diacetylcysteine, N-acetylcysteine–cysteine, N-acetylcysteine–protein, etc.). NAC can be oxidized to a disulfide, N,N′-diacetylcystine, and it still generates mixed disulfides via a reaction with other low-molecular-weight thiols.

Limitations of Current Pharmacokinetic Data

Despite its discovery in the early 1960s and its development for various indications, systematic clinical pharmacology explorations of NAC pharmacokinetics, pharmacodynamic targets, drug interactions, and dose-ranging are sorely limited. This gap in knowledge contributes to the variability of results seen across clinical trials.

5. Scientific Evidence by Area of Use

5.1 Acetaminophen (Paracetamol) Overdose

NAC has FDA approval for the treatment of potentially hepatotoxic doses of acetaminophen (APAP), and it is almost 100% effective if given within 8 hours post-ingestion. This is the most robustly established clinical application of NAC. The mechanism is well understood: liver toxicity from acetaminophen is caused by the reactive metabolite NAPQI, which depletes hepatic GSH and causes cellular necrosis; NAC replenishes GSH and directly detoxifies NAPQI.

NAC is regarded as an effective treatment of paracetamol overdoses. However, in cases of "massive" paracetamol overdoses, recent studies indicate that patients may not be sufficiently treated with the standard dose of NAC (300 mg/kg over 20–21 hours). The NAC dosage for acute acetaminophen overdose is a 140 mg/kg loading dose, followed by a maintenance dose of 70 mg/kg administered every 4 hours for 17 consecutive doses (oral protocol).

Evidence strength: Very strong. FDA-approved, WHO essential medicine designation, with decades of clinical data and near-universal adoption in clinical toxicology.

5.2 Respiratory Diseases

Mucolytic Use (Cystic Fibrosis, Chronic Bronchitis)

NAC is also FDA-approved for use in conditions with abnormal, viscid, or inspissated mucous secretions such as pneumonia, bronchitis, tracheobronchitis, cystic fibrosis, tracheostomy patients, postoperative pulmonary complications, posttraumatic chest conditions and before diagnostic bronchoscopy to help with mucous plugging.

Chronic Obstructive Pulmonary Disease (COPD)

NAC has attracted interest in its potential for treating chronic lung diseases, including COPD, bronchiectasis, cystic fibrosis, and idiopathic pulmonary fibrosis, which are associated with oxidative stress and inflammation. The clinical evidence in COPD, however, is mixed.

A meta-analysis of nine RCTs in COPD found that NAC did not reduce the risk of acute exacerbation or ameliorate the decline in lung volume in COPD patients. Long-term use of NAC has been investigated in six-month to three-year studies examining the efficacy and tolerability of NAC dosed between 600–1200 mg per day in the treatment of COPD. Chikina and colleagues found that the most effective dose of NAC in the treatment of COPD was 1200 mg/day (the study examined doses of NAC ranging from 600–2400 mg/day).

An expert working group undertaking a 2026 consensus review concluded that overall, whether used for acute exacerbations or over extended periods at higher doses (e.g., 600–1,200 mg/day for COPD), NAC is generally very well-tolerated, and in major clinical trials, the overall incidence of adverse events for patients taking oral NAC has consistently been comparable to those taking a placebo.

Evidence strength: Moderate and mixed. Evidence supports high-dose NAC (≥1200 mg/day) having potential benefit in reducing exacerbations, but meta-analyses have not confirmed consistent effects on lung function decline. The 2025 NECTAR expert consensus (published 2026) supports oral NAC for several respiratory indications, though noting study heterogeneity.

5.3 Psychiatric and Neurological Disorders

With the potential to modulate several neurological pathways, including glutamate dysregulation, oxidative stress, and inflammation that can be beneficial to brain functions, NAC is being explored as an adjunctive therapy for many psychiatric conditions.

A major systematic review of clinical trials in psychiatry and neurology found favorable evidence for the use of NAC in several psychiatric and neurological disorders, particularly autism, Alzheimer's disease, cocaine and cannabis addiction, bipolar disorder, depression, trichotillomania, nail biting, skin picking, obsessive-compulsive disorder, schizophrenia, drug-induced neuropathy, and progressive myoclonic epilepsy. Disorders such as anxiety, attention deficit hyperactivity disorder, and mild traumatic brain injury have preliminary evidence and require larger confirmatory studies.

A 2018 narrative review concluded that good evidence exists to support the use of NAC as an adjunct treatment to reduce the total and negative symptoms of schizophrenia. The recommended dosage range for psychiatric conditions derived from this review was 2000 to 2400 mg/day as adjunctive therapy administered concomitantly with existing medications.

Neurological Disorders

A 2026 systematic review mapping clinical evidence across seven neurological disorders (23 studies, covering TBI, Alzheimer's disease, Parkinson's disease, multiple sclerosis, ALS, and migraine) found that the strongest evidence emerged for acute mild TBI, where early NAC administration significantly improved symptom resolution, and for PD, where combined intravenous/oral NAC improved dopamine transporter binding.

Most NAC studies to date have been carried out in animal models of various neurological disorders with only a few studies completed in humans.

Evidence strength: Preliminary to moderate for most psychiatric and neurological conditions. Many studies are small, of short duration, or serve as adjunctive trials. Schizophrenia and addiction have the most replicated positive signals; Alzheimer's disease and TBI results are promising but require larger trials.

5.4 Acetaminophen-Induced and Drug-Induced Liver Injury

The importance of NAC in treating liver failure caused by acetaminophen is well recognized. Off-label indications include acute hepatic failure beyond that caused by acetaminophen alone. Oral NAC undergoes first-pass effects resulting in most of it being taken up by the liver, thus it is effective as a treatment when hepatic GSH levels are depleted with acetaminophen poisoning.

5.5 Non-Alcoholic Fatty Liver Disease (NAFLD)

There is evidence that NAC may block hepatic lipid accumulation and provide therapeutic benefit against metabolic complications found in NAFLD. This is primarily due to its antioxidant effects and attenuation of lipid peroxidation. This is supported by most preclinical studies and a few clinical studies, and there is an urgent need for larger clinical studies.

A 2023 preclinical meta-analysis (13 studies) found that NAC treatment significantly improved systemic and hepatic lipid metabolism (p < 0.01), inflammation-related liver injury (p < 0.01), glucose intolerance (p < 0.05), and hepatic steatosis (p < 0.01) by restoring hepatic GSH and GSH reductase levels compared to controls in NAFLD-induced animals. The authors concluded that NAC has therapeutic potential for NAFLD and should be considered for future clinical trials.

Evidence strength: Preclinical evidence is robust; human clinical trial data are limited and not yet sufficient for clinical recommendations.

5.6 Reproductive Health and Fertility

Polycystic Ovary Syndrome (PCOS) and Female Infertility

The antioxidant properties of NAC have been utilized in multiple clinical trials conducted on infertile PCOS females to increase oocyte quality and ovulation rate. A meta-analysis of 15 RCTs involving 2,330 women concluded that NAC may have a certain efficacy as an adjunct therapy for infertility related to PCOS and unexplained infertility, particularly in women with high BMI, insulin resistance, and oxidative stress. Clinical trials on the effects of NAC supplementation on ovulation and sex hormones profile in women with PCOS have been controversial.

A 2024 pragmatic parallel-group RCT enrolled 230 PCOS women and examined NAC supplementation for ovulation induction efficacy, reporting improvements in endocrine-metabolic profiles. Although these findings still require further validation through rigorously designed RCTs and evaluation of clinical outcomes such as live birth rates over longer follow-up periods, the outcomes suggest that overweight and obese women with PCOS may be a priority population.

Male Infertility

RCT evidence has reported significant improvements in volume, motility, and viscosity of semen, plasma total antioxidant capacity (TAC), and oxidative stress, but not sperm count or morphology, with NAC compared with placebo. An open-label, uncontrolled trial saw significant improvements in sperm motility, count, morphology, and DNA fragmentation, testosterone, LH, FSH, TAC, and oxidative stress. Based on these results, the two mechanisms by which NAC may improve male fertility are thought to be its antioxidant effects as well as effects on the hypothalamus-pituitary-gonadal axis.

Evidence strength: Preliminary to moderate. Meta-analyses suggest benefit for PCOS-associated infertility, particularly in insulin-resistant women, but studies are heterogeneous and few report live birth rates as a primary endpoint.

5.7 Contrast-Induced Nephropathy (CIN)

Prevention of contrast-induced nephropathy is listed as an off-label indication for NAC. However, clinical trial evidence is inconsistent. One double-blind, placebo-controlled RCT (90 patients with diabetes mellitus and chronic kidney disease undergoing cardiac catheterization) found that patients received either oral NAC (600 mg BID, starting 24 hours before the procedure) or placebo in addition to hydration. There were no significant differences between the NAC and placebo groups in the rate of CIN. This result aligns with the broader pattern in the literature, where earlier enthusiasm for NAC in CIN prevention has not been consistently replicated in large, well-controlled trials.

Evidence strength: Evidence is mixed and, on balance, does not support a clear benefit. Earlier positive results have not been replicated in larger and more rigorously controlled trials.

5.8 Cardiovascular Applications

NAC has been shown to potentiate the effects of nitroglycerin and to have antioxidant activity. In the NACIAM trial, the combined treatment of high doses of intravenous NAC (20 mg/min in the first hour and 10 mg/min in the remaining 47 hours) combined with a low dose of nitroglycerin (2.5 μg/min for 48 hours) was effective in reducing the size of acute infarction in patients with ST-segment elevated myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention.

Evidence strength: Preliminary. The NACIAM data are promising for myocardial infarction when combined with nitroglycerin, but the evidence base for cardiovascular indications remains limited in scale and requires larger confirmatory trials.

5.9 Systemic Lupus Erythematosus

NAC replenishes glutathione and, as an antioxidant, is able to inhibit mechanistic target of rapamycin (mTOR) in vitro. A double-blind RCT pilot study using 2.4 g of NAC daily safely and significantly improved lupus disease activity.

Evidence strength: Very preliminary. Only pilot data available; large-scale RCTs are needed.

5.10 Heavy Metal Chelation

NAC may be useful as a chelator for heavy metals and nanoparticles. Its chelation of metals including cadmium, mercury, and lead proceeds through its thiol side chain, and this mechanism has been characterized in biochemical studies, though clinical chelation trials for heavy metal toxicity with NAC specifically remain sparse in comparison to established chelators.

6. Dosage Forms and Dosages Reported in Studies

The following dosages are drawn directly from the clinical literature and should not be interpreted as recommendations:

• Acetaminophen overdose (oral protocol): A 140 mg/kg loading dose, followed by a maintenance dose of 70 mg/kg administered every 4 hours for 17 consecutive doses.
• Acetaminophen overdose (IV standard protocol): 300 mg/kg over 20–21 hours is the standard IV regimen, with debate about adequacy in massive overdoses.
• COPD (oral, long-term studies): 600–1200 mg per day in six-month to three-year studies. The most effective dose in one study examining 600–2400 mg/day was found to be 1200 mg/day.
• Psychiatric/neurological conditions (oral, adjunctive): 2000 to 2400 mg/day as adjunctive therapy.
• Contrast-induced nephropathy prevention: Oral NAC 600 mg BID starting 24 hours before the procedure.
• Acute myocardial infarction (IV, NACIAM trial): 20 mg/min in the first hour and 10 mg/min in the remaining 47 hours, combined with low-dose nitroglycerin.
• Lupus (oral, pilot RCT): 2.4 g of NAC daily.
• General oral bioavailability note: Studies using less than 1200 mg per day may show no significant benefit due to the low oral bioavailability of 4–10%.

7. Body Systems and Health Areas

In addition to its well-recognized use in radiological contrast prophylaxis for renal disease and pulmonary disorders, studies have suggested significant promise in psychiatric and neurological disorders such as addiction, Alzheimer's disease, ataxia, autism, bipolar disorder, depression, epilepsy, neuropathy, obsessive-compulsive disorder, schizophrenia, traumatic brain injury, and trichotillomania, in addition to promising studies in audiology, cardiology, exercise physiology, gastroenterology, hematology, infectious disease, infertility, and ophthalmology.

Organized by system, the principal areas of investigation include:

• Respiratory system: Mucolysis in COPD, cystic fibrosis, bronchiectasis, chronic bronchitis, and idiopathic pulmonary fibrosis.
• Hepatic system: Acetaminophen toxicity antidote, drug-induced liver injury, NAFLD, anti-tubercular drug-induced liver injury.
• Renal system: Contrast-induced nephropathy prevention (off-label, evidence mixed).
• Neurological/psychiatric system: Schizophrenia, bipolar disorder, OCD and related disorders, depression, addiction (cocaine, cannabis), TBI, Alzheimer's disease, Parkinson's disease, multiple sclerosis.
• Reproductive system: PCOS-related infertility, male infertility.
• Cardiovascular system: Myocardial infarction (adjunctive with nitroglycerin), atherosclerosis (preclinical).
• Immunological system: Autoimmune diseases (lupus), HIV-associated GSH depletion.
• Metabolic system: NAFLD, insulin resistance in PCOS.
• Toxicology: Heavy metal chelation, acetaminophen antidote.

8. Safety, Adverse Effects, and Drug Interactions

General Safety Profile

NAC has a well-established safety profile, and its toxicity is uncommon and dependent on the route of administration and high dosages. A meta-analysis of NAC studies found that this supplement was well tolerated, with generally mild, most commonly gastrointestinal, adverse effects that did not require treatment interruption. Systemic allergic reactions to NAC have been observed, but only with intravenous administration. Reflecting its safety profile, NAC is available over-the-counter as a supplement.

Adverse Effects by Route of Administration

• Oral NAC: Adverse reactions reported with oral NAC include nausea, vomiting, diarrhea, headache (especially when used along with nitrates), and rashes. There are rare reports of renal stone formation.
• Intravenous NAC: Undesired effects which may occur during treatment with IV NAC include: anaphylactic shock, anaphylactic reaction, anaphylactoid reaction, hypersensitivity, tachycardia, bronchospasm, dyspnoea, vomiting, nausea, angioedema, urticaria, flushing, rash, pruritus, face oedema, decreased blood pressure, and prolonged prothrombin time.
• Inhaled NAC: Rare reports of bronchoconstriction have occurred with intravenous NAC (but no reports of bronchospasm related to oral use of NAC). Individuals with asthma may be at risk for the potential adverse effect of bronchospasm with inhaled preparations.

Drug Interactions

Nitroglycerin and Nitrates

The vasodilatory and platelet aggregation-inhibiting effects may be enhanced by the simultaneous administration of glyceryl trinitrate (nitroglycerin). The clinical importance of these findings has not yet been determined. If co-treatment with parenteral nitroglycerin and acetylcysteine is considered necessary, the patient should be monitored for potential hypotension, which may be severe and may be indicated by the presence of headache.

Activated Charcoal

Activated charcoal can absorb oral NAC in the stomach, reducing how much gets into the bloodstream. This is clinically relevant in the overdose setting where both agents may be considered simultaneously.

ACE Inhibitors

IV NAC combined with ACE inhibitors (such as lisinopril or enalapril) can cause additive blood pressure-lowering effects.

Anticoagulants and Antiplatelet Agents

NAC may interact with anticoagulants, antiplatelet agents, and NSAIDs, potentially increasing bleeding risk due to its effects on glutathione pathways and free radical scavenging properties.

Antibiotics (Inhaled Combinations)

Reports mentioning inactivation of antibiotics by acetylcysteine relate exclusively to in vitro studies in which the substances were directly mixed. Therefore, NAC should not be co-administered with other medicinal products in the same nebulizer solution.

Vitamin K

Since thiol compounds may form addition compounds with naphthoquinones, there is also the theoretical possibility that a reaction with vitamin K may occur. Although it has not been established whether this can occur in vivo, the administration of vitamin K for the treatment of hypoprothrombinemia in liver failure should begin a few hours after the cessation of acetylcysteine administration.

Pregnancy and Lactation

Data from a limited number of exposed pregnant women showed no adverse effects on pregnancy or the health of the foetus or newborn. Experience from epidemiological studies is not available. Animal studies have not indicated any direct or indirect toxicity with any effect on pregnancy, embryonic development, development of the foetus, or postnatal development. If used during pregnancy, caution is advised. There are no studies showing whether or not acetylcysteine passes into breast milk.

Regulatory and Availability Status

NAC is a drug approved by the Food and Drug Administration (FDA) and recognized by the World Health Organization (WHO) as an essential drug, widely used for the treatment of acetaminophen overdose and more recently as a mucolytic agent in respiratory diseases. Owing to the variety of proposed targets, NAC has a long history of use as a prescription product and in wide-ranging applications that are off-label as an over-the-counter (OTC) product.

Limitations Across the Evidence Base

Despite NAC's relevant therapeutic potential, in several experimental studies, its effectiveness in clinical trials addressing different pathological conditions is still limited. Although NAC is considered a safe substance, the results among clinical trials are sometimes controversial or incomplete, like for many other antioxidants. The low and variable oral bioavailability of 4–10% is a consistent confounding factor, and many early clinical trials used doses that — in light of current pharmacokinetic data — may have been subtherapeutic. The variability in NAC effectiveness may be due to low bioavailability and poor exposure among many other probable causes. In an attempt to circumvent some of those challenges, numerous NAC and cysteine derivatives have been synthesized and tested.

References

• Bavarsad Shahripour R, et al. "A Review on Various Uses of N-Acetyl Cysteine." PMC / NCBI.
• Rushworth GF, Megson IL. "N-Acetylcysteine: A Review of Clinical Usefulness (an Old Drug with New Tricks)." Journal of Nutrition and Metabolism, 2021. PMC.
• Hać A, et al. "N-acetylcysteine Pharmacology and Applications in Rare Diseases—Repurposing an Old Antioxidant." PMC / NCBI, 2023.
• Šalamon Š, et al. "Medical and Dietary Uses of N-Acetylcysteine." Antioxidants, 2019. PMC.
• Mokhtari V, et al. "N-Acetylcysteine (NAC): Impacts on Human Health." PMC / NCBI, 2021.
• Bavarsad Shahripour R, et al. "N-acetylcysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities." Brain and Behavior, 2014. PMC.
• Ooi SL, Green R, Pak SC. "N-Acetylcysteine for the Treatment of Psychiatric Disorders: A Review of Current Evidence." BioMed Research International, 2018. PMC.
• Dean OM, et al. "Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review." Neuroscience & Biobehavioral Reviews, 2015. ScienceDirect.
• Minarini A, et al. "N-acetylcysteine in Neurological Disorders: A Systematic Review of Clinical and Translational Evidence Across Seven Disorders." International Journal of Molecular Sciences, 2026. MDPI.
• Kerksick CM, Willoughby D. "The Antioxidant Role of Glutathione and N-Acetyl-Cysteine Supplements and Exercise-Induced Oxidative Stress." Journal of the International Society of Sports Nutrition, 2005. PubMed.
• Mokhtari V, et al. "N-Acetylcysteine (NAC): Impacts on Human Health." PubMed, 2021.
• Rushworth GF, Megson IL. "Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits." Pharmacology & Therapeutics, 2014. PubMed.
• Abedin MJ. "N-Acetylcysteine." StatPearls. NCBI Bookshelf / NIH, 2024.
• Liao S, et al. "The efficacy of N-acetylcysteine in chronic obstructive pulmonary disease patients: a meta-analysis." PMC, 2023.
• Kerksick CM, Willoughby D. "Anti-Inflammatory and Anti-Oxidant Properties of N-Acetylcysteine: A Fresh Perspective." PubMed, 2024.
• "N-acetylcysteine: Evidence Based Consensus Document on the Therapeutic Advantages in Respiratory Diseases (NECTAR)." Frontiers in Medicine, 2026.
• Chen M, et al. "Comprehensive transcriptomic analysis and meta-analysis identify therapeutic effects of N-acetylcysteine in nonalcoholic fatty liver disease." Frontiers in Pharmacology, 2023. PMC.
• Shen Y, et al. "N-acetylcysteine supplementation improves endocrine-metabolism profiles and ovulation induction efficacy in polycystic ovary syndrome." Journal of Ovarian Research, 2024. Springer.
• Amini M, et al. "N-acetylcysteine does not prevent contrast-induced nephropathy after cardiac catheterization in patients with diabetes mellitus and chronic kidney disease: a randomized clinical trial." Trials, 2009. PMC.
• Arstall MA, et al. "N-acetylcysteine in combination with nitroglycerin and streptokinase for the treatment of evolving acute myocardial infarction." PubMed, 1995.
• Vucicevic Z, et al. "The Pharmacokinetic Profile and Bioavailability of Enteral N-Acetylcysteine in Intensive Care Unit." Pharmaceutics, 2021. PMC.
• Frisher M, et al. "The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine." Springer Nature, 2017.
• Skvarc DR, et al. "Use of N-Acetylcysteine in Psychiatric Conditions among Children and Adolescents: A Scoping Review." PMC, 2018.